Highly sensitive patient-specific real-time PCR SNP assay for chimerism monitoring after allogeneic stem cell transplantation

Laboratory Hematology : Official Publication of the International Society for Laboratory Hematology
Rinat EshelElizabeth Naparstek

Abstract

Chimerism analysis after allogeneic stem cell transplantation (allo-SCT) is an important diagnostic tool for the documentation of engraftment, early detection of graft failure, and recurrence of the disease. Current assays rely on the genetic polymorphism between the donor and the recipient, and allow semiquantitative or quantitative analysis of chimerism. The most common method in use is based on the amplification of the short tandem repeats (STR). This method, with 1% to 5 sensitivity, is useful for the documentation of engraftment, but is insufficient for the detection of minimal residual disease or early relapse, when medical intervention is urgently needed. Recently, single-nucleotide polymorphism (SNP) has been suggested as an alternative, more accurate system to monitor chimerism. The purpose of our study was to develop an easy, economical, and sensitive method for the detection of chimerism following allo-SCT using the SNP technology. Our approach is based on SNP patient-specific quantitative real-time polymerase chain reaction (PCR) using nonlabeled primers. Our results show that this allele-specific SNP real-time PCR approach is sensitive, relatively cheap, and offers a fast and reliable assay for the monitoring of he...Continue Reading

References

Feb 1, 1985·The Journal of Clinical Investigation·D GinsburgJ M Rappeport
Feb 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R H CollinsJ Nemunaitis
Mar 7, 1998·Bone Marrow Transplantation·J R PasswegA J Barrett
Oct 18, 2001·Current Opinion in Hematology·K S Peggs, S Mackinnon
May 2, 2002·Journal of Hematotherapy & Stem Cell Research·F Baron, Y Beguin
Aug 13, 2002·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·F Baron, Y Beguin
Nov 19, 2002·Journal of Human Genetics·Barkur S Shastry
Apr 26, 2003·Mutation Research·Benjamin A SalisburyJ Claiborne Stephens
Sep 6, 2003·Blood·Hans-Jochem KolbDolores J Schendel
Apr 13, 2004·Current Opinion in Oncology·Hans-Jochem KolbChristoph Schmid
Oct 23, 2004·Best Practice & Research. Clinical Haematology·Nuhad Haddad, Jacob M Rowe

❮ Previous
Next ❯

Citations

Dec 6, 2008·The Journal of Molecular Diagnostics : JMD·Egle GineikieneLaimonas Griskevicius
Nov 10, 2009·Expert Review of Molecular Diagnostics·Egle GineikieneLaimonas Griskevicius

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.